• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    Novel phenylethanolamine derivatives represented by the formula <IMAGE> wherein R represents a hydrogen atom, a halogen atom, a hydroxyl group, a lower alkyl group, a lower alkoxy group, a lower alkylthio group, an amino group, a lower acylamino group, a lower alkylsulfonyl group, or a lower alkylsulfonylamino group; R1, R2, R3 and R4, which may be the same or different, each represents hydrogen or a lower alkyl group; R5 represents an aryl group which may have a substituent, a benzodioxane ring group which may have a substituent, an aryloxy group which may have a substituent, or an arylthio group which may have a substituent; said R5 being, however, a benzodioxane ring group which may have a substituent, an aryloxy group which may have a substituent, or an arylthio group which may have a substituent when R is a hydroxyl group; and n represents 0 or an integer of 1-3 and the acid addition salts thereof. The compounds of this invention exhibit alpha - and beta -adrenergic blocking actions and are useful as antihypertensive agents.
    公开号:SU932982A3
    申请号:SU792835396
    申请日:1979-10-18
    公开日:1982-05-30
    发明作者:Имаи Казуо；Ниигата Кунихиро；Фудзикура Такаси；Хасимото Синити
    申请人:Яманоути Фармасьютикал Ко., Лтд. (Фирма)；
    IPC主号:
    专利说明:

    the values of n are defined above. These compounds contain 1-4 asymmetric carbon atoms, and, specifically, include racemic compounds, their mixtures and optically active substances. The separation of the racemate is carried out in the usual way, for example, by fractional crystallization or separation of the benzyl derivative of formula I using chromatography on silica gel, followed by debenzylation of the benzyl derivative. The method consists in the fact that the halohydrin or epoxide of the general formula, where Y is hydroxy ;, X is halogen or X and Y together form epoxy R has the indicated values, is treated with an amine of the general formula HjH-CR R-lCHaln P1 where P is as indicated above, in an organic solvent medium, and, if necessary, convert the resulting desired product to its salt. As a rule, ethanol is used as an organic solvent, the process is carried out at reflux for 3-6 h, the target product is isolated by column chromatography on silica gel. Example 1. A mixture of 3.3 g of 1-methy-3-phenygschropylamine, 5 O ml of ethanol and 2.5 g of 3- (2-bromo-1-hydroxyethyl) benzosulfonamide is heated under reflux for 4 hours with stirring. After cooling the reaction mixture, ethanol is distilled from vacuum. The residue is dissolved. in 5O ml of benzene, the precipitated crystals were melted off, the benzene was distilled off in vacuo. The resulting oily to co-substance was then chromatographed on a column of silica gel, eluted with a mixture of chloroform and ethanol (8.5: 1.5, by volume) and 1.1 g of a viscous oily substance were obtained. This substance is again chromatographed on a silica gel column, epyuated with a mixture of ethyl acetate and methanol (9; 1, by volume) to obtain 0.4 g as 3-1-hydroxy-2- (1-methyl "-3-phenylpropylamine) -eti l -benzene lonfamida In the form of amo (xx)) powder. The product has the following physical and chemical properties: 1) amorphous form 2) elemental analysis: Calculated,%: C 62.04; H 6.94; N 8.04 2 Found,%: C 62.13; H 6.88; N 8.06 3) NMR spectrum (CDCP), ppm: 1.03 (3N, d CHCH) 4.60 (1H, m CHON) Example 2. 2.1 g (0.012 g) was dissolved in 20 O ml of ethanol. mol) of the (1,) 1- (1,4-benzodioxan-2-yl) ethylamine isomer and 1.4 g (0.006 mol) of 2-chloro-5epoxyethylbenzenesulfonamide. The solution is boiled under reflux for 3 hours with stirring, the ethanol is distilled off in vacuo and a viscous oily product is obtained, which is chromatographed on a column of silica gel, and elution is carried out with ethyl acetate. The ethyl acetate is then completely distilled off in vacuo and 1.1 g of isomer (-i) 2-chloro-5-1-hydroxy-2- (1,4-benzodioxan-2-yl) ethylamine benzolyltrophonamide are obtained. Properties of this product: 1) amorphous form 2) analysis Calculated,%: C 52.36; H 5.1E; N 6.78 CjgHjiNjOsSCe Found,%: C 52.09; H 5.21; N 6.52 3) NMR Spectrum (SOSSd), parts per million: 1.12 (3N, d of CH 2 SNR), 4.67 (1H, C SION). 4) mass spectrum: 412 (). . According to the procedure of Example 2, the compounds of Examples 3-9 are obtained. Example 3. 2-Chloro-5- 1-hydroxy-2- (1-methyl-3-phenylpropylamine) ethylbenzoylsu lolonamide. Physical and chemical properties: 1) amorphous form 2) analysis Calculated,%: C 56.46; H 6.05; N 7.32 C | gH2jN20, jSC Found,%: C 56.67; H 6.18; N 7.29 3) NMR (CO2), parts per million: 1.05 (MN, d CHCH) 4.60 (1H, q, СНОН) 4) mass spectrum: 382. (M) Example 4. Hydrochloride 3-chloro-5-1-hydroxy-2- (1-metip-3-phenipropylamine) ethyl benzene lonamide. Physical and chemical properties: 1) amorphous form 2) analysis Calculated,%: C 51.55; H 51.77 6.68 Found: C 51.35; H 5.74; N 6.41 3) NMR (+ DjO + N a2COz), part per million: 1, O9 (3N: d CHCHj) 4.72 (IH, m SNON), Example 5. 5-G1-Oxy-2- ( Methyl l-3-pheny lpropyl H) -ethyl l -2-methi l thiobenzene sulfonam. Physical and chemical properties 1) t. PP 1O9-110 ° C 2) analysis Calculated,%: C 57.84; H 6.64; N 7.10 s) Found. %: C 57.54; H 6.77; N 6.93. 3) NMR (COVZ), part / million: 1.12 (MN, d CHCHj). 2.58 (3N, 5 CH); 4.70 (IH, m CHOH),. Example 6. 5- {1-Oxy-2- 2- (-chlorophenoxy) -G-methy-ethyl lamindate-2-methylbenzenesuponamide. Physical and chemical properties: 1) amorphous form 2) analysis Calculated,%: C 54.20; H 5.81; Ы 7.02 Found,%: C 54, O2; H 5.67; N 6.66 3) NMR (COCES), part / mpn: 1.15 (GD, d SNSN). 2.6O (3N, S en.4, 70 (1H, t СНОН). Example 7. 5-1-hydroxy-2- (1-M tyl-3-pene or propynammin) -ethyl -2-methylsulfonylbenoolsulfonamide. Physical and chemical properties: 1) t. square 136-145 ° C 2) analysis Calculated,%: C 53.5; H 6.14; M 6.54 Ci9 Hj jNjOgSj Found;% C 53.61; H 5.94; U 6.63 3) NMR (d-DMCO), parts per million: 1.0 (3H, d CHCHj), 3.92 (ZN, 5 CHiSO 4.87 (ZN, m SNON). Example 8. Fumarate 2-bromine -5 - 1-hydroxy-2- (1-methyl-3-phenylpropyl-these are l-benzene of lonfamide. Physical and chemical properties: 1) amorphous form 2) Analysis Calculated,%: C 49.49; H 5.19; S 5.77 C of CrOsVr Found: C, 49.76; H 5.28; 5 5.51 3) NMR (dfe-uMCO), parts per million: 1.29 (GPR, m CHCH), 5.02 (1H, m CHOH). Example 9. 5-1-hydroxy-2- 2- (2-methoxyphenoxy-1, 1-dimethylethylamine laminPetyl1-2-methybe nzolsu lonfamid. Physical and chemical properties: 1) mp. 161-162 ° C 2) analysis Calculated,%: C 58.80; H 6.91; 6.86; Found: C 58.52; H 7.11; N 6.67 3) NMR (CDce + dfc-DMCO), part per million: 1.17 (6H, S C (CH3) 2). 2.64 (ЗН, S, CH ,, 3.79 (ЗН, 5 OCHj), 4.64 (1Н, CJ СНОН). Example Y. 2.26 g of 2-phenylthioethylamine are dissolved in 7.0 MP of ethanol. After adding to a solution of 3 g of 5-epoxyethyl-2-methylbenelolesulfonamide, the mixture is boiled under reflux for 6 h. After cooling the reaction mixture, the ethanol is distilled off in vacuo and a light oily product is obtained. This product is silica gel on a silica gel column and subsequently heated with a mixture of benzene and ethyl acetate (1: 1, by volume), these by lamb and a mixture of ethyl acetate and methanol (9: 1, by volume) receive 85O mg of light-yellow oil The product is crystallized from a small amount of isopropanol, filter w 1 is filtered off, washed with ether c, 385 mg of 5-1-hydroxy-2- (2-phenylthioethnpamine) ethyl -2-methylbenzopulsulfonate are obtained in the form of colorless crystals. The product has the following physical and chemical properties: 1) t. square 100.5-103.5 ° C 2) elementary analysis: Calculated,%: C 55.71; H 6.05; N 7.64; S 1b, 5O .. Found,%: C 55.46; H 6.12; N 7.62; S 17,22 3) NMR spectrum (CDCBi + d-DMCO), ppm: 2.64 (ЗН,, 4.69 (1H, m СНН).
    According to the procedure of Example 10, the joints of Examples 11-26 are obtained.
    Example 11. 2-Chloro 1-hydroxy 2- (2-phenyptoyethylamine) ethyl 1-benzenesulfonamide hydrochloride.
    Physical and chemical properties:
    1) amorphous fsfma
    2) analysis
    Calculated,%; C 45.39; H 4.76; N 6,62
    Cj HigceNjOgS her
    Found %; C 45.26; H 7.79; N 6.54
    3) NMR {d, -DMCO + CDCe3 + Ilp +), part / million: 4.62 {lH,: j, SIW
    Example 12. Chlorhydryd 5- | 1 - hydroxy-2- 2- (4-.chlorophenoxy) -ethylamine is ethyl l-2-methybenzenesulfonamide.
    Physical p chemical properties:
    1) t. square 169-172 ° C.
    2) analysis
    Calculated,%: C 48.46; H 5.26; N 6,65
    S.N2, N204500
    . Found,%: e 48.37; H 5.23; N 6.51
    3) NMR (d -DMeo + DjO + Najeo,
    part / million: 2,64 (ЗН, 6
     4.8
    yeno
    {1n, sh enon).
    Example 13. 5-l-OKCH-2- 2-) xi-2-methoxyphenoxy) -ethylamine 1 these-2-methylbenzenesulfonamide.
    Physical and chemical properties:
    1) t. square 18 9-191 0
    2) analysis
    Calculated,%: e 54.53; H 6.10; W 7.07
    C | yN24 aAb5
    Found,%: e 54.46; H 6.19; N 7.13.
    3) NMR (db-DMeO), ppm; 2.58 (ЗН,, -) 3.68 (ЗН, 5
    Oenz), 4.92 (1H; m enrn).
    Example 14. (4-Al-2-methoxyphenoxy) -ethylamine -1-hydroxyethyl -2-methylbenzenesulfonamide.
    Physical and chemical properties:
    1) t, pl. 152-154 ° e
    2) analysis
    Calculated,%. e 59.98; H 6.71; N 6,66
    ejiH gWjCgS
    Found,%: e 59.88; H 6.79; N 6.74
    3) NMR (df, - DMeO), ppm; 2.60 (ЗН, S-, еН, -) 3.76 (ЗН, S
    OH;), 4.76 (1n, t enone).
    Example 15. 5-1-hydroxy-2- 2-hydroxymethylphenoxy) -ethylamine-ethyl (-2-methane nsolsulfonamide.
    Physical and chemical properties: 1) m. Pl. 129-13 Oe
    2) analysis
    Calculated,%: C, 56.83; H 6.36; N 7.36
    Found,%: e 56.69; H 6.43; N 7.44
    3) NMR (d-DMeO), ppm: 2.56 (3N, 5 eN3-O) 4.03 (2H, -t,), 4.51 (2H, S eH2OH): 4.68
    (1H, -t enone).
    Example 16. 2-Chloro-5- 1-hydroxy-2- 2- (2-methoxyphenoxy) -1-methyethylamine -ethyl l (-benzene lonfamide.
    Physical and chemical properties:
    1) t. square 176-179 ° e
    2) analysis
    Calculated,%: e 52.11; H 5.59; N 6.27
    e, aH23eEN.; 05S
    Found,%: e 52.19; H 5.66; N 6, O9
    3) NMR (de, - vmeo + eoe5) part /
    / Million: 1.15 (ZN, d ENEN), 3.82 (ZN,
    5, oen.), 4.85 (1n, m enone).
    Example 17. 2-Methyl-5- 2-. - (1,1-dimethyl-2-phenoxyethyl amine) -l-oxyethyl-benzenesulfonamide.
    Physical and chemical properties:
    1) t. square 184-185 ° e
    2) analysis
    Calculated,%: e 60, DA; H 6.92; N 7.40
    19 26 2-4
    Found,%: e 6O, 36; H 7.04;
    N 7.45
    03) NMR (s1b-SMEO), part / million:
    1.12 (6H, 5 e (eH2) 2). 2.62 (3N, 5 C1C-C, 3.76 (2H, 5 eH20), 4.68
    (iH, -t enone).
    Example 18. (2-Allyl-5-hydroxyphenoxy) -ethylamine -1-hydroxyethyl-2 methane in the forehead of nzolsulfonamide.
    Physical and chemical properties:
    1) t. square 141-142 ° e
    2) analysis
    Calculated,%: e 54.23; H 6.14; N 6.32
    S2o 2b r055-ne
    Found,%: e 53.98 H 6.17; N 6.48
    5 3) NMR (dfo-PMeO + DjO + Na eOi), parts per million: 2.64 (3N S eDn-h} -. 8
    v.j-ri, m enon) ,, 6,08- (iH, m ЫйснleHj). Example 19. 5- (l-OKCH-2-t§- (4-chloro-2-methoxyphenoxy) etipamine ethyl -2-methipbenzene suphonamide. Physical and chemical properties: 1) t. pp 124-126 ° C 2) anapia Calculated,%: C 52.11; And 5.59; N 6.75 Cig. Found,%: C 52.24; H 5.48; W 6,69 3) NMR (dfe-DMCO) ,, ppm 2.57 (3N, 5 3.77 (3N, 5 OCHj), 4.68 (1H, mCHOH), Example 20. (2-phenoxy-acetyl) ethylamine -1-hydroxyethyl -2-meth benone-lfonamide. Physical and chemical properties: mp. 1О4-1О6 ° С 1) 2) analysis С 58.15; H 6.16; Calculated N 7.14 C 57.99; H 6.07; Found, N 7.11 3) NMR (dfe-DMCO), part / million: 2.48 (6H, - 5 CHj-O + U (1H, m snon). Example 21. Chlorohydrate 2- {4-carbomoylphenoxy) -ethylamine} -1 -oxyethyl-2-methylbenzene sulfonamide. Physical and chemical properties, 1) t. square 180-182С 2) analysis Calculated,%: C 50.29, H 5.63; 9.77 s-Hce with 50.11; H 5.78; Found, N 9.51 3) NMR (dfe-DMCo + DjO + Na coa), parts per million: 2.58 (3N, S t N CH2CH2), 4.08 (2H, t (2H, 20), 4 , 68 (lH, t СНОН). CHjCH Example 22. 5-1-hydroxy-2-2 - (2-allyloxyphenoxy) ethylamine 2-ethyl-2-methoxybenzene lfonamide. Physical and chemical properties: 1) t. square 156-158 ° C 2) analysis Calculated,%: C 56.86; H 6.20; Vi 6.63; Found: 56.55; H 6.24; N 6.67 3) NMR (d -DMCO), parts per million: 2.72 (2H; d), 2.92 (2H, t.), 3.90 (3N, 5 OCH), 4.03, (2H, -t CH2CH20), 4.40-4.80 (MN, stsnsn-sn + snon). , EXAMPLE 23. 5- 1-Oxy-2- {2- (2-carbamoiphenoxy) -ethylamine 3-ethyl-1-2-methylesu is pefonamide. Physical and chemical properties: 1) t. square 148-150s 2) analysis Calculated,%: C 54.95; H 5.89; and 10.68 CigHj-N O-S Found,%: C 55.10; H 5.91; N 10.74 3) NMR (d6-DMCO), part / mpn: 2.59 (3N, 5,) 2.74 (2H, d CHCHjN), 3.01 (2H, t CH2CH2N), 4.22 (2H. t CHjCHjO), 4.73 (IH, t CHOH), Example 24..:; p-2- 3- (4-hydroxyphenyl) -1-methylpropylamino} -ethe l - 2 -me lbe: zopsufamide hydrochloride. Physical to chemical properties: amorphous form. Example 25. 5-1-hydroxy-2- 2- (2-ethylphenoxy) -ethylamino-ethyl -2-methipbenzenesulfonylamide hydrochloride. . Physical and chemical properties: pl. 153-155 ° c. Example 26. (2-Methoxy-4-methoxycarbonylphenoxy) -ethipamino -1-hydroxyethyl | -2-methipbenzenesulfonylide. Physical and chemical properties: t. Pl. 142-144 ° C. The pharmacological effect of the compounds obtained is determined as follows. The effects of typical compounds of the invention are compared with the action of 5-l-hydroxy-2 - (1-methy l-3-phe nor lpropi l) -ami-no-ethylT-sapicyl amide (common name labetalol). A. 0 -Adrenoblocking effect: a) blood pressure is measured in rats anesthetized with urethane and treated with pentoliniam. The effect of the samples (intravenous injection) is measured in order to antagonize the hypertensive reaction to phenylferin (10 µg / kg intravenously). The test results are shown in Table. 1. c) (-adrenoblokiruyuschuyu action is determined by the method of Tkhikava, Takenaka and sotr, 197-3. The frequency of the heartbeat in rats, which are previously administered reserpine (8 mg / kg intraperitoneally) for 1 h hours, is determined rats are anesthetized with phenobarbitit 4 (55 mg / kg intraperitoneally) and cut the vagus nerve on the tail. with spontaneous hypertension: Intravenous administration. blood pressure and heart rate are determined by direct measurement of blood pressure in rats with spontaneous hypertension, in which the systological blood pressure is higher than 15 mm Hg, according to the method of Mirogi et al 1969. The test results are given in Table 2., . -, 6-adrenergic blocking activity Table
    clH- (iH2-i "H-d ((iH2) ni (I)
    I4, b
    HE
    Treatment: Values are the average i correction based on the results of experiments on 5-1 O animals.
    权利要求:
    Claims (2)
    [1]
    Invention Formula
    The method of obtaining 2-hydroxy-2-phenylethylamine derivatives of the formula
    35 t
    Antihypertensive effect Table. Change in systological pressure Compound blood, mm Hg. Art. at 10 mg / kg through the mouth supplied by -25 ± 4.2 -lit 3.3 -34t 5.2 weight (labelol) -10 ± 3.6
    de - hydrogen, halogen, lower a lk and L-, alkoxy, alkylthio or alkylsulfonyl;
    and R is the same or different, aquatic genus ish nor: shy alkyl; R is arip, which may contain a lower alkoxy or hydroxy group as a substituent; benzodiosane cyclic group; a phenoxy or phenylthio group which may contain one or two substituents such as halogen, hydroxy, methoxy, acetyl, carbamoyl, lower alkyl, alkoxy, alkoxycarbonyl, alkenyl and alkenyloxy;
    P - O or 1-3,
    or their salts.
    They are based on the fact that hapogengid {zh or epoxide of the general formula II
    NgN $ Og x
    . “„ CiH-dHz-X Y - hydroxy group;
    X is halogen, or X and Y together form an epoxy cycle; R - has the indicated values, is treated with an amine of the general formula III
     HjN-CR R-tCHalnR I
    13
    where and P - as indicated above, in a de organic solvent, followed by isolation of the target products in free form or in the form of their salts.
    Priority featured:
    12.10.77 when K is hydrogen, lower alkyl or lower apkoxy;
    26,10.77 with R - lower alkylthioyl or lower alkoxy:
    12.23.77 when R and R - hydrogen;
    06.Ab.78 when R is aryl, aryloxy-.
    14 which may contain
    ari lthio group, substituents.
    Sources of information taken into account in the examination
    1. Mashkovsky MD Drugs, M., Medicine, 1972, vol. 1, p. 217-226.
    2. Byuler K. and Pearson D. Organic syntheses. M., Mir, 1973, t. 1,
    [2]
    with. 504-507, 529-53.
    类似技术:
    公开号 | 公开日 | 专利标题
    SU932982A3|1982-05-30|Process for producing 2-hydroxy-2-phenylethylamine derivatives or their salts
    Confalone et al.1977|Stereospecific total synthesis of d-biotin from L |-cysteine
    SU1428199A3|1988-09-30|Versions of method of producing derivatives of 2,2,3-iminobisethanol or acid-additive salts thereof,or stereochemical isomeric forms thereof
    EP1780197B1|2010-10-20|5-substituted-2-phenylamino benzamides as mek inhibitors
    CA1180021A|1984-12-27|Substituted carbamoyloxy derivatives ofphenylethanolamine
    EP0132392B1|1992-01-02|Asymmetric synthesis of alpha-substituted-alpha-cyanomethyl alcohols
    DD143607A5|1980-09-03|METHOD FOR PRODUCING NEW CARBAZOLYL- | -OXY-PROPANOLAMINE DERIVATIVES
    DE2805404A1|1979-08-16|1-ARYLOXY-3-NITRATOALKYLAMINO-2-PROPANOLS AND METHOD FOR THE PRODUCTION THEREOF
    AU609359B2|1991-04-26|New indolylpropanols, processes for their preparation and their use, and preparations containing the compounds
    SU1172449A3|1985-08-07|Method of producing phenylalkylamine derivatives or salts thereof
    SU1620049A3|1991-01-07|Method of producing derivatives of 4-|-pyperidine butanamide or their stereo isomers, or pharmaceutically acceptable acid-additive salts
    US4145422A|1979-03-20|Aminomethylene oxindoles
    US4293700A|1981-10-06|2,6-Dimethyl-1,4-dihydropyridine-3,5-dicarboxylic acid esters and method for preparing same
    US4450172A|1984-05-22|Antihypertensive polyhalohydroxyisopropyl phenylalka|noic acid esters of alkylaminohydroxypropyloxyphenylalkyl alcohols
    CH679859A5|1992-04-30|
    SU795469A3|1981-01-07|Method of preparing uracyl derivatives
    AU667280B2|1996-03-14|Benzylamine derivatives
    EP0116628A1|1984-08-29|1-acyl-3-pyridylmethylguanidines and their use as antihypertensive agents.
    KR820000508B1|1982-04-10|Process for preparation of phenyl ethanolamine derivates
    US4176191A|1979-11-27|Aminomethylene oxindoles
    KR820000521B1|1982-04-12|Process for the preparation of phenylethanol amine derivatives
    US5137908A|1992-08-11|4-azahexacyclododecane compounds
    KR820000522B1|1982-04-12|Process for the preparation of phenylethanol amine derivatives
    SU1366053A3|1988-01-07|Method of obtaining substituted benzamides,their solvates or hydrates or salts thereof
    PT89272B|1993-07-30|METHOD FOR PREPARING NEW PHENYLALKYLAMINE DERIVATIVES USED IN THE TREATMENT OF MENTAL PETURBACOES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
    同族专利:
    公开号 | 公开日
    FR2405931B1|1982-11-19|
    ES481549A1|1980-04-01|
    NO783442L|1979-04-18|
    AU4064278A|1980-04-17|
    CA1147342A|1983-05-31|
    CH639948A5|1983-12-15|
    DE2843016C2|1988-10-13|
    GB2006772A|1979-05-10|
    PT68624A|1978-11-01|
    SU982537A3|1982-12-15|
    NO147148B|1982-11-01|
    IT1160853B|1987-03-11|
    SE448232B|1987-02-02|
    ATA731778A|1981-01-15|
    DK168484B1|1994-04-05|
    GB2006772B|1982-02-03|
    DE2843016A1|1979-04-26|
    IT7869350D0|1978-10-11|
    DK452178A|1979-04-13|
    GR65337B|1980-08-18|
    US4217305A|1980-08-12|
    ES474149A1|1979-10-16|
    NO147148C|1983-02-09|
    FR2405931A1|1979-05-11|
    AU526715B2|1983-01-27|
    AT363457B|1981-08-10|
    SE7810613L|1979-04-12|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US3701808A|1967-12-21|1972-10-31|Allen & Hanburys Ltd|Phenylethanolamines|
    GB1266058A|1969-07-08|1972-03-08|
    GB1321701A|1969-10-01|1973-06-27|Continental Pharma|Amino-alcohols their salts and process for prepairing the same|
    US3711545A|1971-02-23|1973-01-16|Smith Kline French Lab|Alpha-aminoalkyl-4-hydroxy-3-sulfamoylaminobenzyl alcohols|
    DE2115926C3|1971-04-01|1978-05-03|C.H. Boehringer Sohn, 6507 Ingelheim|1 - -2-aminoether derivatives, process for their preparation and compositions containing them|
    US4034112A|1973-06-22|1977-07-05|Imperial Chemical Industries Limited|Ethanolamine derivatives having β-adrenergic blocking activity|
    US3860647A|1973-08-20|1975-01-14|Smithkline Corp|{60 -Aminomethyl-4-hydroxy-3-sulfamyl-benzyl alcohols and 4-hydroxy-3-sulfamyl phenethylamines|
    GB1593651A|1977-02-03|1981-07-22|Allen & Hanburys Ltd|Amides|
    DK31578A|1977-02-03|1978-08-04|Allen & Hanburys Ltd|PROCEDURE FOR THE PRODUCTION OF BENZENE DERIVATIVES|JPS6215062B2|1979-03-20|1987-04-06|Kyowa Hakko Kogyo Kk|
    US4206125A|1979-05-04|1980-06-03|Richardson-Merrell Inc.|5-[2-[amino]-1-hydroxyethyl]-2-hydroxybenzoic acid derivatives|
    DD202692A5|1979-12-04|1983-09-28|Ciba Geigy|PROCESS FOR THE PREPARATION OF NEW DERIVATIVES OF 2-AMINO-AETHANOL|
    US4558156A|1980-02-08|1985-12-10|Yamanouchi Pharmaceutical Co., Ltd.|Sulfamoyl-substituted phenethylamine derivatives|
    US5391825A|1980-02-08|1995-02-21|Yamanouchi Pharmaceutical Co., Ltd.|Sulfamoyl substituted phenethylamine intermediates|
    JPS6252742B2|1980-02-08|1987-11-06|Yamanouchi Pharma Co Ltd|
    DE3128117A1|1980-07-29|1982-03-11|Yamanouchi Pharmaceutical Co., Ltd., Tokyo|NEW PHENYL-AETHYLAMINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF|
    CA1219865A|1982-05-14|1987-03-31|Leo Alig|Aziridine phenethanolamine derivatives|
    PT78388B|1983-04-12|1986-09-15|Smithkline Beckman Corp|Dopamine-beta-hydroxylase inhibitors|
    JPH0443049B2|1983-08-31|1992-07-15|Yamanouchi Pharma Co Ltd|
    DE3564569D1|1984-05-15|1988-09-29|Seitetsu Kagaku Co Ltd|Process for preparing 2-alkyl-5-haloacetylbenzenesulfonamide|
    US4678855A|1985-10-09|1987-07-07|Merck & Co., Inc.|Substituted benzenesulfonamides|
    JPH0137391B2|1985-11-13|1989-08-07|Yamanouchi Pharma Co Ltd|
    IE883400L|1987-11-13|1989-05-13|Fuisz Technologies Ltd|Phenethanolamine derivatives|
    US5663205A|1992-05-22|1997-09-02|Senju Pharmaceutical Co. Ltd.|Pharmaceutical composition for use in glaucoma treatment|
    FR2737494B1|1995-08-04|1997-08-29|Synthelabo|BENZENESULFONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION|
    ES2208772T3|1996-01-10|2004-06-16|Asahi Kasei Kabushiki Kaisha|NEW TRICYCLE COMPOUNDS AND PHARMACEUTICAL COMPOUNDS THAT CONTAIN THE SAME.|
    WO1999057131A1|1998-05-06|1999-11-11|Duke University|Method of treating bladder and lower urinary tract syndromes|
    FR2791675B1|1999-03-30|2001-05-04|Synthelabo|DERIVATIVES OF N- [2-ETHYL] -2,3-DIHYDRO-1,4- BENZODIOXINNE-2-METHANAMINE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION|
    US6835853B2|2001-10-31|2004-12-28|Synthon Bv|Process for resolution of tamsulosin and compounds, compositions, and processes associated therewith|
    DE60336485D1|2002-08-19|2011-05-05|Pfizer|COMBINATION THERAPY AGAINST HYPERPROLIFERATIVE DISEASES|
    KR20060021870A|2003-05-30|2006-03-08|랜박시 래보러터리스 리미티드|Substituted pyrrole derivatives and their use as hmg-co inhibitors|
    KR100596373B1|2003-12-09|2006-07-04|씨제이 주식회사|Processes for preparing optically pure phenethylamine derivatives|
    KR20070084455A|2004-11-23|2007-08-24|워너-램버트 캄파니 엘엘씨|7--3,5-dihydroxy-heptanoic acid derivatives as hmg co-a reductase inhibitors for the treatment of lipidemia|
    GT200600381A|2005-08-25|2007-03-28|ORGANIC COMPOUNDS|
    US7741317B2|2005-10-21|2010-06-22|Bristol-Myers Squibb Company|LXR modulators|
    EP1948599A1|2005-11-08|2008-07-30|Ranbaxy Laboratories Limited|Process for -7-[2--5-isopropyl-3-phenyl-4- [ carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt|
    US7888376B2|2005-11-23|2011-02-15|Bristol-Myers Squibb Company|Heterocyclic CETP inhibitors|
    EP2026766A1|2006-05-17|2009-02-25|Synthon B.V.|Tablet composition with a prolonged release of tamsulosin|
    WO2008070496A2|2006-12-01|2008-06-12|Bristol-Myers Squibb Company|N--2, 2--propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases|
    US8465770B2|2008-12-24|2013-06-18|Synthon Bv|Low dose controlled release tablet|
    CN102050766B|2009-11-03|2013-08-07|安徽省新星药物开发有限责任公司|Synthesis method for amosulalol hydrochloride|
    CA2909442A1|2013-04-17|2014-10-23|Pfizer Inc.|N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases|
    WO2016055901A1|2014-10-08|2016-04-14|Pfizer Inc.|Substituted amide compounds|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    JP12203477A|JPS5473751A|1977-10-12|1977-10-12|Phenyl ethanolamine derivatives and their preparation|
    JP12843677A|JPS5463048A|1977-10-26|1977-10-26|Novel phenyl ethanolamine derivatives and their preparation|
    JP15535277A|JPS5747185B2|1977-12-23|1977-12-23|
    JP7496478A|JPS552639A|1978-06-21|1978-06-21|Phenylethanolamine derivative and its preparation|
    [返回顶部]